Multimodal Data Integration for the Prediction and Prevention of Chronic Heart Failure: A Prospective Cohort Study

Multimodal Data Integration for the Prediction and Prevention of Chronic Heart Failure: A Prospective Cohort Study - Multimodal Data Integration of Chronic Heart Failure: A Prospective Cohort Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061087

Enrollment

750

Registered

2026-03-27

Start date

2026-03-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients across all heart failure stages, including those at risk for heart failure, those with structural heart disease without heart failure, those with prior or current heart failure, and those with refractory heart failure

Exclusion criteria

Exclusion criteria: Patients in whom obtaining informed consent for study-related procedures is difficult

Design outcomes

Primary

Measure	Time frame
The primary endpoints are major adverse cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, and hospitalization for unstable angina, heart failure, stroke, or other cardiovascular events, as well as all-cause mortality. The occurrence of events will be assessed every 12 months after enrollment through review of medical records or patient interviews. The incidence of cardiovascular events will be analyzed using Kaplan-Meier survival curves, and prognostic factors will be identified based on candidate predictors derived from imaging, biomarker, and genetic data.	—

Measure

Time frame

The primary endpoints are major adverse cardiovascular events, defined as cardiovascular death, nonfatal myocardial infarction, and hospitalization for unstable angina, heart failure, stroke, or other cardiovascular events, as well as all-cause mortality. The occurrence of events will be assessed every 12 months after enrollment through review of medical records or patient interviews. The incidence of cardiovascular events will be analyzed using Kaplan-Meier survival curves, and prognostic factors will be identified based on candidate predictors derived from imaging, biomarker, and genetic data.

—

Countries

Japan

Contacts

Public ContactMasayoshi Oikawa

Fukushima Medical University Department of cardiovascular medicine

moikawa@fmu.ac.jp024-547-1190

Outcome results